ThursdayAug 23, 2018 10:04 am

Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP) Drug Delivery Platform Takes Dosage from Zero to 203 in 15 Minutes

DehydraTECH™ methodology offers safer alternative to smoking Possible nicotine delivery platform for Big Tobacco Several licensing agreements for technology already signed Formula One racing is not the only place to find speed. The drug delivery platform DehydraTECH™, developed by Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP), has proven that it’s just as fast. In recent in vivo tests, the technology delivered 203 nanograms per milliliter (ng/mL) of nicotine in 15 minutes, 70 percent more than the control. Such rapidity may rival smoking; particularly as new research (http://cnw.fm/gi1Aw) suggests that “nicotine takes much longer than previously thought to reach peak levels in…

Continue Reading

WednesdayAug 22, 2018 9:00 am

As Senate Brings Legal Change, Hemp Offers Hope for American Farmers

PsychedelicNewsWire Editorial Coverage: The hemp industry is growing in North America and appears to be set for further expansion thanks to legislation making its way through the U.S. Senate. Hemp is a cultivar of the cannabis sativa plant that lacks the active drug ingredient that makes marijuana users high. It can be used to produce medicinal CBD oil as well as fibers for rope, paper and canvas. Even in difficult growing conditions, hemp can provide higher profits than many other crops. It has a lower environmental impact thanks to low water consumption and little need for chemical fertilizers or pesticides.…

Continue Reading

FridayAug 17, 2018 1:42 pm

Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP) Sees Progress in Revolutionary Alternative to Smoking for Drug Delivery

Smoking-related deaths have reached six million a year worldwide Lexaria’s patented drug delivery platform aims to deliver commonly smoked drugs in a non-smoking form factor that sidesteps smoking’s hazards Second round of testing continues to indicate that patented DehydraTECH™ platform provides rapid delivery with high bioavailability As world drug industry regulations undergo revolutionary change and increasingly healthy populations find themselves challenged to meet the cares of old age, Canadian biotechnology company Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP) is forging a path that establishes it as a pioneer in the field of drug delivery platforms. Lexaria’s mission is to ensure…

Continue Reading

ThursdayAug 16, 2018 1:47 pm

PreveCeutical Medical Inc.’s (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H) Medicinal Cannabis Division Targets Treatment Option for Anxiety Disorders

Anxiety is implicated in several chronic physical illnesses including heart disease, respiratory disorders and gastrointestinal conditions Scientific evidence in several studies shows that CBD exhibits anti-inflammatory and anti-anxiety properties Newly created medicinal cannabis division will focus on development of cannabinoids as preventative treatment for anxiety disorders Use of PreveCeutical’s proprietary Sol-gel nasal delivery platform for cannabinoid therapy promises ease of use, sustained release, better efficacy Preventative medicine industry represents a $3.8 trillion market Health sciences company PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H) is tackling a topic that many people hesitate to bring up – anxiety disorders, including…

Continue Reading

WednesdayAug 08, 2018 9:00 am

Specific Therapeutic Benefits of Cannabidiol (CBD) Validated by FDA

PsychedelicNewsWire Editorial Coverage: In a landmark announcement, the U.S. Food and Drug Administration (FDA) recently approved a drug derived from pure cannabidiol (CBD), Epidiolex, to treat seizures associated with certain forms of severe epilepsy, setting the stage for huge changes in the world of cannabidiol (CBD). FDA approval of a cannabis-based drug represents seismic political, legal and economic shifts Approval likely will lead to more clinical research and further validation of CBD therapeutic efficacy CBD market projected to explode to more than $2 billion in two years with 39 percent CAGR What’s most transformative about this drug approval is that…

Continue Reading

ThursdayAug 02, 2018 12:11 pm

Phivida Holdings Inc. (CSE: VIDA) (OTCQX: PHVAF) is “One to Watch”

Publicly traded on the Canadian Securities Exchange (CSE.VIDA) and recently graduated to the OTCQX Best Market in the USA (OTCQX.PHVAF) Strong balance sheet and capital structure with over CAD $15.5 million cash, no debt, with less than 60 million shares outstanding – fully capitalized for global distribution Expert management team includes former senior executives from Red Bull, Proctor & Gamble, Labatt’s, Stoli Group and the former CEO of Seagram’s International Joint venture with top Canadian licensed producer WeedMD (TSX: WMD) for one of the first federally legal cannabis beverage manufacturing facility, new global distribution partners Developing best-in-class premium CBD-hemp oil…

Continue Reading

PsychedelicNewsWire Currently Accepts

Bitcoin

Bitcoin

Bitcoin Cash

Bitcoin Cash

Ethereum

Ethereum

Litecoin

Litecoin

USD Coin

USD Coin

Contact us: 415.949.5050